View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 19, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Revolution Medicines to Report Financial Results for Fourth Quarter an...

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a we...

Alicia Reese ... (+11)
  • Alicia Reese
  • Anish Jog
  • Chase Tohanczyn
  • Daniel Ives
  • Kade Barr
  • Matthew McCartney
  • Matthew Weiss
  • Michael Piccolo
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig
Alicia Reese ... (+11)
  • Alicia Reese
  • Anish Jog
  • Chase Tohanczyn
  • Daniel Ives
  • Kade Barr
  • Matthew McCartney
  • Matthew Weiss
  • Michael Piccolo
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 6, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 4, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Revolution Medicines to Participate in Guggenheim Securities Emerging ...

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast ...

Anish Jog ... (+7)
  • Anish Jog
  • Chase Tohanczyn
  • Daniel Ives
  • Matthew Weiss
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig

The Software Armageddon is Here; 5 Names to Buy in this "Software Gara...

MSFT - We believe that Microsoft is on its way to accelerating cloud and AI monetization, which is going to comprise a bigger piece of Redmond going forward and will ultimately spur growth and margins over the coming years. While Anthropic has seen significant advancements in model performance and

Anish Jog ... (+5)
  • Anish Jog
  • Daniel Ives
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig

Set Up for Another Robust Year from Messi of AI on the Back of US Comm...

A Closer Look at FY4Q25 (December) ResultsRevenueTotal revenue of $1.407 billion (up 70% y/y and 19% q/q) came in above both the company’s guidance range of $1.327 billion to $1.331 billion and the Street’s $1.340 billion estimate driven by the continued acceleration of its US business in both gove

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 2, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 31, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Revolution Medicines Doses First Patient in Clinical Trial Evaluating ...

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The first-in-human trial, RMC-5127-001 [], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 27, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Michael Piccolo
  • Michael Piccolo

Daily Recap: WBD/NFLX,LKQ,SKYT/IONQ, LE,HOLX,GME,BOBS,ONL,CCA,PUM,CRM,...

Warner Bros. Discovery, Inc. (WBD - $28.24) and Netflix Inc. (NFLX - $85.70)News Reports Senate Antitrust Panel Chair Raises Concerns Over Pending Merger. According to the WSJ, Senator Mike Lee, chairman of the Senate Judiciary Committee's Subcommittee on Antitrust, Competition Policy & Consume

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch